REG - RUA Life Sciences - AGM Statement and Trading Update

Rua Life SciencesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260317:nRSQ8538Wa&default-theme=true

RNS Number : 8538W  RUA Life Sciences PLC  17 March 2026

RUA LIFE SCIENCES PLC

("RUA", the "Company" or the "Group")

AGM Statement and Trading Update

 

 

RUA Life Sciences (AIM: RUA), the medical device businesses focused on
implantable textiles and the leading biostable polymer (Elast-Eon™),
provides the following update on trading and business developments since the
audited results for the 18 months to September 2025 (the "September Results")
to coincide with the Company's Annual General Meeting taking place later
today.

 

As intimated at the time of announcing the September Results in January,
activity levels have continued into the current period, and the Board is
encouraged by recent developments.

 

Contract Development and Manufacturing (CDMO)

The UK based Contract Development and Manufacturing business generates
revenues from both development contracts and manufacturing contracts, with a
business model in which successful development projects have the potential to
transition into manufacturing contracts.

 

The majority of CDMO revenue is generated by two Manufacturing contracts which
continue to perform with similarly strong activity levels seen in the final
six months of the September Results period. Importantly, in that six-month
period, the business was successful in executing development projects which
generated revenues of c.£175,000. The current period has seen further
progression of this Contract Development work and agreed proposals and open
purchase orders now total approximately £500,000 which should be billed
during the current financial year but will be weighted towards the second half
of the financial year. It is positive that around 60% of the projects relate
to approved products or products in the final stage of regulatory approval
providing the opportunity for Contract Manufacturing revenues to follow on in
the shorter term. The potential annual contract value for the manufacture of
these products if they progress from Contract Development to Manufacturing is
expected to be in excess of £5 million per annum.

 

Abiss, the Group's France-based manufacturer of implantable devices, is
trending under budget at present as a major customer seeks to reduce its
inventory position. RUA is currently in discussions with the customer to align
inventory holdings whilst providing revenue visibility for two years.

 

Separately, Abiss has its own portfolio of medical devices, including a
next-generation mini-sling for the treatment of Stress Urinary Incontinence
and is developing a strategy to exploit these product opportunities.

 

Biomaterials

During the Period, RUA Biomaterials has traded broadly in line with the
corresponding months of the September Results period. Further growth is
anticipated through a new contract for the use of Elast-Eon and the outcome of
an audit of historical royalties from licensees.

 

Heart Valve Development

As stated in the Annual Report, the Company is undertaking development work
within RUA Structural Heart in support of interest expressed for the use of
AurTex(TM) for a specific heart valve need. At the time, the Board also
confirmed its objectives of having future activities funded by third parties.
RUA is pleased to confirm that the Company is close to achieving this
objective through the recent signing of a Heads of Terms to secure funding to
undertake the pre-clinical development of a novel heart valve incorporating
AurTex. Shareholders will be further informed of this development at the
appropriate time.

 

 

Bill Brown, Group CEO commented "RUA has reached a key inflexion point in its
growth having achieved our initial targets of doubling the scale of the CDMO
business, we now have the visibility for this rate of growth to continue. It
is also a credit to the RUA team that the value of the IP and products being
developed are being recognised by customers and partners alike and we look
forward to further step changes in the business."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation (2014/596) which is part of UK law by virtue of
the European Union (Withdrawal) Act 2018, as amended and supplemented from
time to time.

For further information contact:

 RUA Life Sciences
 Bill Brown, CEO     Tel: +44 (0)1294 317073
 Lachlan Smith, CFO

 

Cavendish Capital Markets Limited

(Nominated Adviser and Broker)
                                            Tel:
+44 (0)20 7220 0500

Giles Balleny/Isaac Hooper (Corporate
Finance)

Harriet Ward (Broking)

Nigel Birks (Healthcare Specialist Sales)

Michael Johnson (Sales)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTEAPDKFENKEFA



            Copyright 2019 Regulatory News Service, all rights reserved